Pre-Clinical (Discovery and Development)

Find out how to fill up your pipeline and increase innovation. Pharma IQ is proud to provide an international, non-biased, central resource, for professionals working in early discovery and preclinical research to exchange ideas on best practice and share case studies on innovation within the area.
 


Conference Round-Up: The 12th Annual Global Biobanking Summit and The Compound & Sample Management Conference - Pharma IQ

Back due to popular demand, the co-location of IQPC’s 12th Annual Global BiobankingSummit alongside the Compound and Sample Management Conference took place last week. Full Article »


Events related to this topic:

Utilising Big Data for Bioscience Product Development

Contributor: Diana Davis
Posted: 7/3/2014


Utilising Big Data for Bioscience Product Development - Diana Davis

Big data is turning up everywhere. In this Process Perspectives podcast, Kaare Buch Petersen, Information Architect in Global IT at Christen Hansen, a Denmark-based supplier of bioscience products to food and health industries, talks about how his company has been using big data in the development of their new products. Full Podcast »


Events related to this topic:

The Halo(gen) Effect in para-Substituted Phenyl Rings

Contributor: Jonas Boström
Posted: 2/26/2015


The Halo(gen) Effect in para-Substituted Phenyl Rings - Jonas Boström

One key to successfully progress a drug discovery project is to make first-rate decisions (hopefully) based on unambiguous data. This is not trivial since our scientific problems are often very complex and data can be fuzzy. In drug design we try to approach this uncertainty by being rational. It is however sometimes forgotten that our rational approaches may not be that rational after all – decisions may well be based on personal preferences and intuitive biases.... perhaps unconsciously made on biased data. Full Column »


Events related to this topic:

Market Snapshot - Top 10 Biosimilars Manufacturers 2015

With the approval of the first biosimilar product in the United States this year, cost containment pressures and a pending patent cliff, Pharma IQ takes a closer look at the current biosimilars market. Full Whitepaper »


Events related to this topic:



Advertise With Us

Join the Pharmas IQ Community